A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?

BACKGROUND: Ovarian cancer (OC) is the sixth most common cancer in women. Currently, carboplatin/paclitaxel ± bevacizumab is the cornerstone of front-line treatment. Conversely, the therapeutic options for recurrent or progressive disease are not well defined. For platinum-sensitive patients the bes...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Staropoli, Nicoletta, Ciliberto, Domenico, Botta, Cirino, Fiorillo, Lucia, Gualtieri, Simona, Salvino, Angela, Tassone, Pierfrancesco, Tagliaferri, Pierosandro
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2013
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3599392/
https://ncbi.nlm.nih.gov/pubmed/23388584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1757-2215-6-10
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items